Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects

Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects

Source: 
Fierce Pharma
snippet: 

Novartis filed a registration statement with the SEC for the spinoff of its eye-care unit, Alcon. It hasn't placed a valuation on the transaction just yet, but previous CEO Joe Jimenez said last year it could be worth as much as $35 billion.